Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Neoplasm Metastasis, TAMK (TAM kinase), MER (mer proto-oncogene), MERTK (mer proto-oncogene tyrosine kinase), AXL (AXL receptor tyrosine kinase), AXL/MER, Selective kinase inhibitor, PD-1 (programmed cell death protein 1), PD-L1 (programmed cell death ligand 1), Immune modulator, Advanced Cancer, Metastatic Cancer, Solid Tumor Cancer, Metastatic Solid Tumor, Cervical Cancer, Gastric Cancer, Esophageal Cancer, Endometrial Cancer, Hepatocellular carcinoma (HCC), Melanoma, Merkel Cell Carcinoma, High levels of MicroSatellite Instability deficient MisMatch Repair (MSI-H-dMMR) tumor, Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC), Renal cell carcinoma (RCC), Urothelial carcinoma, Colorectal cancer (CRC), Axitinib, Sasanlimab
Lead Scientist at University of California Health
- Adil Daud (ucsf)
Professor, Medicine, School of Medicine. Authored (or co-authored) 196 research publications
- in progress, not accepting new patients
- Start Date
- Completion Date
- To obtain contact information for a study center near you, click here.
- Phase 1 research study
- Study Type
- About 67 people participating
- Last Updated